Merck Strategy and Business Model

Executive Overview

Merck is a U.S.-based research-driven pharmaceutical company with a second major business in animal health. Known as MSD outside the United States and Canada, Merck sells prescription medicines, vaccines, biologic therapies, and veterinary products across most major healthcare markets. Its portfolio is anchored by Keytruda in oncology and Gardasil/Gardasil 9 in vaccines, while products such as Bravecto, Nobivac, and livestock monitoring and identification solutions give the Animal Health segment a distinct second leg. Merck’s strategy, as reflected in recent annual reporting, investor materials, and 2024 deal activity, is to combine internal research with licensing, partnerships, and acquisitions to build multiple growth engines beyond Keytruda ahead of that franchise’s eventual loss of exclusivity later this decade. The company is headquartered in Rahway, New Jersey, traces its U.S. roots to 1891, and operates a global network of research, manufacturing, and commercial sites. In 2023, Merck reported $60.1 billion of revenue, with the Pharmaceutical segment contributing the large majority and Animal Health adding diversification, steadier repeat demand, and exposure to different end markets.

Merck at a Glance

Logo
Common name	Merck
Full legal name	Merck & Co., Inc.
Headquarters	Rahway, New Jersey, United States
Ownership	Public company; widely held institutional ownership
Ticker	MRK
Exchange	NYSE - New York Stock Exchange
Market Cap	$295.67B
Revenue (FY2024)	$64.17B
Founding / major historical milestones	Founded in 1891 as the U.S. arm of Merck; became an independent U.S. company during World War I; merged with Sharp & Dohme in 1953; acquired Schering-Plough in 2009; spun off Organon in 2021.
Industry or industries	Pharmaceuticals, vaccines, biologics, animal health
Key products or services	Prescription medicines, vaccines, oncology therapies, hospital and specialty medicines, veterinary pharmaceuticals, animal vaccines, livestock identification and monitoring solutions
Geographic footprint	Global; operates as MSD outside the United States and Canada
Business segments as officially reported	Pharmaceutical; Animal Health
Company website	https://www.merck.com/

1. What Is the Strategy of Merck?

Merck’s public strategy is best understood as an innovation-led portfolio strategy: use internal science, late-stage development skill, global manufacturing, and selective business development to create a diversified set of high-value medicines and vaccines, while keeping Animal Health as a second growth platform. The practical issue sitting behind many recent decisions is concentration risk around Keytruda. Merck’s strategic moves in 2023 and 2024 show a clear effort to broaden the company’s earnings base before that product faces loss of exclusivity later this decade.

1. 1a. What is the winning aspiration of Merck?

   Merck’s stated corporate purpose is to use leading-edge science to save and improve lives. Strategically, “winning” appears to mean something more specific: remain one of the world’s most important innovation-based biopharma companies while reducing dependence on any single asset. In practical terms, that means sustaining strong cash generation from current blockbusters, launching new franchises in specialty care and vaccines, and building a broader late-stage pipeline through both internal discovery and external deals. Management’s recent actions suggest that Merck wants to emerge from the Keytruda era as a company with several meaningful growth platforms rather than one dominant oncology product.

2. 1b. Where does Merck play?

   Merck plays in branded, science-intensive markets where clinical differentiation, regulatory expertise, and manufacturing quality matter more than lowest cost. Its core playing fields are oncology, vaccines, hospital and specialty medicines, infectious disease, selected chronic-care medicines, and animal health. Geographically, it competes globally across developed and emerging markets. Channel-wise, it plays through large healthcare systems, hospitals, specialist prescribers, public-health buyers, wholesalers, and veterinary channels. The 2021 Organon spin-off sharpened that playing field by moving Merck away from slower-growth women’s health, biosimilars, and some established brands and toward innovative medicines, vaccines, and animal health.

3. 1c. How does Merck plan to win?

   Merck does not try to win on price. It tries to win through differentiated clinical outcomes, strong evidence generation, trusted global supply, and the ability to scale commercialization around important launches. Keytruda is the template: broad clinical development, multiple indications, combination therapy leadership, and global market access. Merck is now trying to repeat that formula in adjacent areas through products such as Winrevair and through externally sourced assets such as Prometheus’s immunology program and the Daiichi Sankyo antibody-drug conjugate alliance. The company’s recipe is to pair strong science with disciplined portfolio management and enough financial flexibility to buy or license new engines when internal research is not sufficient.

4. 1d. What capabilities must Merck have in place?

   To execute that strategy, Merck needs several capabilities at world scale: discovery biology and translational medicine; large, global clinical-development operations; regulatory affairs; biologics and vaccine manufacturing; commercial execution with specialty prescribers and payers; pharmacovigilance and quality systems; and sophisticated business-development and alliance-management capabilities. In Animal Health, it also needs veterinarian relationships, livestock channel access, and digital identification and monitoring know-how. The company’s pattern of partnerships and acquisitions suggests that Merck views external-science sourcing as a core capability, not a side activity.

5. 1e. What management systems does Merck require?

   Merck requires management systems that can balance long-cycle R&D bets with near-term commercial execution. That includes stage-gated portfolio review, rigorous capital-allocation processes, launch-governance systems, manufacturing quality and supply-planning disciplines, and enterprise risk management for safety, compliance, and product continuity. In a business where a single late-stage trial result or a single manufacturing issue can move billions of dollars of value, execution systems matter as much as strategy statements. Merck’s recent record implies a management model built around portfolio prioritization, disciplined external dealmaking, and close coordination among research, manufacturing, regulatory, and commercial teams.

2. What Are the Current Strategic Initiatives of Merck?

• Defend and extend the Keytruda franchise. Merck continues to invest heavily in new indications, earlier-stage treatment settings, and combination regimens for Keytruda. A subcutaneous formulation has also been part of the company’s public development agenda, which would improve convenience and could help support franchise durability. The collaboration with Moderna on individualized neoantigen therapy V940 is another example of Merck trying to deepen the Keytruda ecosystem rather than treat Keytruda as a static mature brand.

• Build a broader oncology portfolio beyond checkpoint inhibition. Merck’s 2023 alliance with Daiichi Sankyo around three antibody-drug conjugates and its 2024 acquisition of Harpoon Therapeutics show a clear push into new oncology modalities. This is strategically important because Merck needs more than one mechanism of action to sustain oncology leadership after Keytruda’s exclusivity window narrows.

• Launch new specialty-care growth drivers. In 2024, Merck began the commercial launch of Winrevair in pulmonary arterial hypertension after U.S. approval. That product matters not only for revenue growth but also for portfolio balance because it expands Merck’s presence in a specialty cardiovascular market with different prescribers and reimbursement dynamics than oncology.

• Refresh and broaden the vaccine portfolio. Merck has continued investing in Gardasil supply and in new vaccine candidates, including V116 for adult pneumococcal disease and clesrovimab for infant respiratory syncytial virus prevention. Vaccines are strategically attractive for Merck because they can create durable franchises, public-health relevance, and a customer base different from oncology.

• Use business development to enter or deepen adjacent therapy areas. The 2023 acquisition of Prometheus Biosciences added a late-stage immunology asset, while the announced 2024 EyeBio transaction signaled interest in ophthalmology. Merck has been explicit that external science is a major source of future growth, especially where it can buy time-to-market or platform capabilities.

• Expand manufacturing capacity and resilience. Merck has publicly announced significant capital spending on biologics and vaccine manufacturing, especially in the United States. This is not just an operations issue; it is strategic, because product availability can constrain growth in vaccines and biologics just as much as demand can.

• Keep Animal Health growing as a second operating engine. Merck continues to invest in companion-animal products, livestock medicines, and digital identification and monitoring capabilities from the Antelliq acquisition. Animal Health gives Merck recurring demand, a different competitive cycle from human pharma, and a business less exposed to the same patent-cliff pattern.

3. What Is the Business Model of Merck?

Merck’s business model is primarily the sale of patent-protected or otherwise differentiated medicines, vaccines, and animal-health products. This is not a subscription model and not a commodity manufacturing model. Customers pay for clinical efficacy, safety, regulatory approval, brand trust, and reliable supply.

• What customers actually buy: In human health, customers buy branded prescription therapies, vaccines, and specialty medicines that improve outcomes in cancer, infectious disease, cardiopulmonary disease, diabetes, and hospital settings. In Animal Health, customers buy veterinary pharmaceuticals, vaccines, parasiticides, and livestock identification and monitoring systems.

• Recurring versus one-time revenue: Much of Merck’s revenue is repeat-driven. Oncology medicines like Keytruda are used over multiple treatment cycles. Chronic-care medicines generate repeat prescriptions. Vaccines are more episodic but can still be durable through public-health schedules, booster patterns, and successive cohorts of eligible patients. Animal Health tends to be especially repeat-oriented, driven by preventive care, herd-health programs, and ongoing veterinary relationships.

• How pricing power works: Merck has pricing power when a product is clinically differentiated and protected by patents, exclusivity, or brand position. But that power is constrained by rebates, payer negotiations, government purchasing, tendering systems, and international price controls. In other words, Merck has more strategic pricing leverage than a commodity producer, but much less than a pure luxury brand.

• Why the business mix matters: Product mix has an outsized impact on economics. Keytruda and Gardasil are not just large products; they are major profit pools. Animal Health is smaller but important because it diversifies Merck away from a single human-health patent cycle. Legacy products such as Januvia and Janumet still contribute revenue but carry less strategic growth weight than newer oncology, vaccine, and specialty assets.

• What drives gross margin, operating margin, and cash generation: Gross margin benefits from intellectual property, scale, and the high value of successful medicines. It is pressured by product mix, biologics and vaccine manufacturing complexity, collaboration profit-sharing, royalties, and occasional inventory or manufacturing charges. Operating margin depends heavily on R&D intensity, launch spending, and business-development costs. Cash generation can be very strong once a product scales because manufacturing costs are often far lower than the economic value of a successful therapy.

• Revenue model: Revenue is primarily recognized from product sales, with some collaboration and alliance economics where Merck co-develops or co-commercializes assets with partners such as AstraZeneca, Eisai, and Moderna.

4. What Products and Services Does Merck Sell?

Pharmaceutical

Merck’s Pharmaceutical segment is the core of the company and includes oncology, vaccines, hospital acute care, infectious disease, and selected primary-care or specialty medicines.

• Oncology: Keytruda is the company’s flagship product and by far its most important commercial asset. Merck also participates in oncology through collaboration products such as Lynparza and Lenvima and through newer assets like Welireg. Oncology is the segment’s biggest revenue and strategic driver.

• Vaccines: Gardasil and Gardasil 9 are major growth products in human papillomavirus prevention. Merck also sells established pediatric and adult vaccines, including products such as M-M-R II, Varivax, ProQuad, RotaTeq, and Vaxneuvance.

• Hospital and specialty medicines: Bridion is an important hospital product, and Winrevair became a new specialty-care launch in 2024. Merck also markets products in infectious disease and other specialty categories.

• Legacy and established brands: Products such as Januvia and Janumet remain commercially meaningful but no longer define Merck’s growth story the way oncology and vaccines do.

Animal Health

Merck’s Animal Health business sells pharmaceuticals, vaccines, biologics, and technology-enabled solutions for both companion animals and livestock.

• Companion animals: Key offerings include parasiticides such as Bravecto and vaccine lines such as Nobivac.

• Livestock: Merck sells vaccines, anti-infectives, fertility-management products, and health-management tools for cattle, poultry, swine, aquaculture, and other production animals.

• Identification and monitoring: Through brands such as Allflex and SenseHub, Merck also offers animal identification, traceability, and monitoring systems. These are strategically important because they give the business a technology and data dimension beyond traditional veterinary medicine.

In economic terms, Keytruda appears to be Merck’s largest revenue and profit contributor, with Gardasil/Gardasil 9 as another major engine. Animal Health is smaller but strategically meaningful because it broadens the company’s end markets and cash-flow profile.

5. What Are the Key Competitors or Peers of Merck?

Merck does not have one single rival across all businesses. Its closest competitors vary by therapeutic area, vaccine category, and animal-health niche.

Beyond these branded peers, Merck also competes with generic and biosimilar entrants when exclusivity ends, and with substitute treatments that can shift standards of care even before patent expiry.

6. What Is the Marketing Strategy of Merck?

Merck’s marketing strategy is science-led rather than mass-market-led. In human health, the most important commercial levers are clinical evidence, physician adoption, formulary access, reimbursement, and trust in supply and safety. Traditional brand advertising matters in some categories, especially vaccines and certain U.S. prescription products, but it is not the primary source of competitive advantage.

• Specialist and institutional marketing: Merck invests heavily in medical education, congress presence, key-opinion-leader engagement, and evidence communication to specialists, hospitals, and health systems.

• Market access and payer engagement: Payer strategy is central because the buyer in pharmaceuticals is often not the end user. Merck must secure formulary access, reimbursement, and placement with managed-care organizations and government programs.

• Selective consumer marketing: In the United States, direct-to-consumer advertising can support awareness for selected prescription products and vaccines, but Merck’s core performance still depends more on clinical positioning than consumer promotion.

• Animal Health channel marketing: In Animal Health, marketing is more channel- and relationship-driven. Veterinarians, distributors, and livestock producers are key decision makers, so field education, practice support, technical service, and brand trust matter greatly.

Overall, marketing at Merck is a supporting capability to clinical differentiation and access. It matters, but it does not replace the need for superior data and broad regulatory approvals.

7. What Are the Key Customer Segments of Merck?

Merck is diversified across end markets, but economically it remains highly tied to global healthcare reimbursement systems and, in Animal Health, to veterinary and livestock channels.

8. What Is the Sales Model of Merck?

Merck uses a hybrid sales model built around direct commercialization, wholesalers and distributors, institutional accounts, and selected partnerships.

• Human health channels: In many markets, Merck sells to large pharmaceutical wholesalers and specialty distributors, which then serve pharmacies, hospitals, and clinics. Some products, especially vaccines and hospital medicines, may also be sold directly to providers, health systems, or government agencies.

• Specialty commercial model: Products such as Keytruda and Winrevair require specialist-focused field teams, medical-science liaison support, market-access teams, and account management with integrated delivery networks and payers.

• International sales structure: Merck generally uses local subsidiaries and affiliates outside the United States, sometimes supplemented by local distribution or promotion partnerships. In China, for example, Merck has used local partnership structures for parts of its vaccine commercialization.

• Animal Health channels: Animal Health sells through distributors and directly to veterinarians, producers, and livestock operations, depending on product category and region.

This channel structure gives Merck scale and reach, but it also means that growth and pricing are shaped by intermediary economics, channel inventory patterns, reimbursement, and contracting. For consultants, that creates opportunities in account strategy, launch execution, channel design, and distributor management.

9. In What Geographies Does Merck Operate?

Merck operates globally and is marketed as MSD outside the United States and Canada. The United States is its single most important market, but Merck is not a U.S.-only company. Europe, China, Japan, Latin America, and other international markets are material to both the Pharmaceutical and Animal Health businesses.

Operationally, Merck has a broad footprint that includes corporate leadership in Rahway, New Jersey; major research and development activities in the United States; and a global manufacturing and commercial network across North America, Europe, Asia-Pacific, Latin America, and other regions. Merck has substantial manufacturing investments in the United States and also important production capacity in countries such as Ireland and Singapore. Animal Health likewise operates through a global network of manufacturing, distribution, and technical-service assets.

The geographic mix matters strategically for three reasons. First, it diversifies Merck’s revenue base across reimbursement regimes. Second, it exposes the company to different vaccine-adoption curves and public-health priorities. Third, it makes supply-chain execution and regulatory coordination much more complex, especially for biologics, vaccines, and temperature-sensitive products.

10. Who Are the Owners of Merck?

Merck is a publicly traded company with no disclosed controlling shareholder. As of the company’s 2024 proxy period and contemporaneous institutional filings, its largest shareholders were major asset managers such as The Vanguard Group, BlackRock, and State Street. Ownership is therefore broadly institutional rather than founder-controlled, family-controlled, or government-controlled.

11. How Is Merck Organized?

At the reporting level, Merck is organized into two segments: Pharmaceutical and Animal Health. That official structure is straightforward, but the practical organization is more layered.

• Pharmaceutical: This segment includes human prescription medicines and vaccines across oncology, vaccines, hospital acute care, infectious disease, cardiopulmonary, and other therapeutic areas.

• Animal Health: This segment includes companion-animal and livestock products, plus identification, traceability, and monitoring capabilities.

• Merck Research Laboratories: R&D is centrally important and functions as a major enterprise capability spanning discovery through late-stage development.

• Global manufacturing and commercial functions: These support both segments, with regional market organizations and centralized quality, regulatory, supply, and corporate functions.

Merck is not a loose holding company. It is better understood as a globally integrated science-and-commercialization organization with two operating segments and strong centralized enterprise capabilities.

12. How Does Merck Operate?

On a day-to-day basis, Merck operates as an end-to-end discovery, development, manufacturing, and commercialization system.

1. Research and portfolio building: Merck discovers molecules internally and supplements its pipeline through licensing, alliances, and acquisitions.

2. Clinical development and regulatory execution: The company runs global clinical trials, prepares regulatory submissions, and works with health authorities across regions to gain or expand approvals.

3. Manufacturing and quality release: Merck produces small molecules, biologics, vaccines, and animal-health products in a highly regulated network. Quality systems, validation, and batch release are critical operating activities.

4. Commercialization and market access: The company supports launches and ongoing sales through field teams, medical affairs, payer contracting, distributor management, and public-health relationships.

5. Lifecycle management: Merck continually seeks new indications, formulations, combinations, geographic expansion, and label updates to extend product relevance and returns.

The operational bottlenecks are typical of large pharma but particularly important at Merck’s scale: clinical-trial execution, manufacturing capacity for biologics and vaccines, regulatory timing, and the ability to launch new products fast enough to offset aging franchises.

13. What Are the Growth Opportunities for Merck?

Merck’s most plausible growth opportunities are closely tied to the company’s public effort to diversify beyond Keytruda while still extracting more value from that franchise.

• New oncology platforms: Antibody-drug conjugates, T-cell engagers, and personalized cancer vaccines could give Merck new oncology growth drivers that complement rather than simply repeat Keytruda.

• Specialty-care launches: Winrevair gives Merck a foothold in pulmonary arterial hypertension. Prometheus adds a possible immunology platform, and the announced EyeBio deal points to potential ophthalmology expansion.

• Vaccines: Gardasil still has room to grow where demand exceeds supply, and late-stage candidates such as V116 and clesrovimab create possible new vaccine revenue streams.

• Animal Health and digital livestock: Merck can deepen its mix of pharmaceuticals, vaccines, traceability, and monitoring tools in livestock and companion animals.

• Geographic expansion and adult immunization: Emerging-market access and broader adult vaccination can support additional growth, especially where public-health infrastructure and reimbursement improve.

• Further business development: Merck has the balance-sheet capacity and demonstrated willingness to buy pipeline assets or platforms that accelerate diversification.

The main constraints are equally clear: eventual Keytruda exclusivity loss, clinical-development risk, manufacturing scale-up risk, payer and pricing pressure, and the difficulty of integrating acquisitions quickly enough to matter before major patent cliffs arrive.

14. What Is the History of Merck?

Merck’s U.S. business was founded in 1891 as the American arm of the German Merck enterprise. During World War I, the U.S. business became independent, which is why today’s Merck & Co. is separate from Germany’s Merck KGaA. In 1953, Merck merged with Sharp & Dohme, creating the basis for the MSD name used outside the United States and Canada.

Merck spent decades building a reputation as a major research-based pharmaceutical company. A transformative modern milestone came in 2009 with the acquisition of Schering-Plough, which expanded scale and diversified the portfolio. In 2021, Merck spun off Organon, sharpening its focus on innovative medicines, vaccines, and animal health. It then accelerated science-led business development through acquisitions such as Acceleron in 2021 and Prometheus in 2023. More recent 2024 transactions, including Harpoon and the announced EyeBio deal, show that Merck’s history has become increasingly shaped by targeted external pipeline building rather than only internal discovery.

15. What Are the Key Suppliers to Merck?

Suppliers matter materially to Merck because pharmaceuticals and vaccines depend on specialized, validated inputs that are not always easy to switch. Merck does not publicly provide a broad named list of strategic suppliers, but its disclosures indicate that some materials and third-party manufacturing arrangements are single-source or limited-source.

• Active ingredients and biologic inputs: Chemical intermediates, active pharmaceutical ingredients, cell-culture media, resins, adjuvants, and other specialized biologics materials.

• Sterile fill-finish and packaging components: Vials, stoppers, syringes, cartridges, and sterile containers are critical, especially for injectable drugs and vaccines.

• Single-use manufacturing systems and equipment: Bioprocess bags, filters, tubing, and related consumables can create bottlenecks if supply is tight.

• Contract manufacturing and services: Merck uses external manufacturers and service providers for selected products, materials, and development activities.

• Animal Health inputs: Vaccine antigens, fermentation materials, hardware for identification systems, and livestock technology components are important in Animal Health.

Supplier structure matters strategically because switching approved suppliers can require validation work, regulatory updates, and time. In a launch or shortage environment, that can directly affect revenue.

16. What Are the Key Brands Owned by Merck?

Brands matter at Merck, but in different ways by business. In human pharmaceuticals, brand value is tied to clinical evidence, trust, and reimbursement. In Animal Health, branding can be even more commercially visible because veterinarians and producers often buy within established product families.

The corporate brand also matters: Merck uses the MSD name outside the United States and Canada, which is an important practical distinction in global markets.

17. How Is Merck Using AI?

Merck has publicly positioned artificial intelligence as an enabling capability across research, development, and operations rather than as a standalone product line. The clearest use cases are in data-rich parts of the business where pattern recognition and prediction can improve speed or decision quality.

• Drug discovery and design: AI and machine-learning tools can support target identification, molecular design, protein engineering, and prioritization of compounds for further study.

• Clinical development: Merck has signaled interest in analytics that improve trial design, patient selection, site performance, and data interpretation.

• Manufacturing and quality: AI can be used in process monitoring, predictive maintenance, deviation analysis, and supply planning in complex manufacturing environments.

• Animal Health analytics: Digital livestock-monitoring platforms give Merck a natural place to use analytics and AI in herd management and animal-health monitoring.

Public disclosures suggest that some AI uses are already embedded in scientific and operational workflows, while broader generative-AI applications appear to be an active area of experimentation and scaling rather than a finished enterprise transformation.

18. How Does the Supply Chain of Merck Function?

Merck’s supply chain is a highly regulated global network that links specialized sourcing, long-cycle manufacturing, stringent quality release, cold-chain logistics, and multi-channel distribution.

• Sourcing: Merck procures complex chemical and biologic inputs, packaging components, equipment, and external manufacturing services. Some inputs are specialized enough that dual sourcing can be difficult.

• Manufacturing: The company operates both small-molecule and biologics/vaccine production. These processes have different lead times and constraints, but both require current good manufacturing practice discipline and regulatory compliance.

• Quality and release: Batch testing and release are essential, especially for biologics and vaccines. This means supply is not just about making product; it is also about validating, releasing, and documenting it properly.

• Distribution: Merck ships through wholesalers, specialty distributors, providers, and government or public-health channels. Cold-chain capability is critical for many products.

• Service logistics in Animal Health: Animal Health adds another layer because the company supports veterinary clinics, livestock producers, and hardware-enabled monitoring systems.

Supply-chain reliability is strategically important for Merck because shortages can limit growth in high-demand franchises, damage trust with public-health buyers, and reduce the value of expensive launches.

19. What Are the Key Assets of Merck?

Merck is asset-intensive in the way large pharmaceutical companies usually are: the most important assets are a mix of intellectual property, regulated manufacturing capacity, scientific talent and infrastructure, and global commercial access.

• Intellectual property and exclusivities: Patents, regulatory data packages, know-how, and brand equity around products such as Keytruda and Gardasil are among Merck’s most valuable assets.

• Merck Research Laboratories: The company’s research engine and pipeline are core value-creating assets.

• Manufacturing network: Biologics and vaccine capacity, sterile production, and validated global plants are major barriers to entry.

• Commercial infrastructure: Relationships with regulators, providers, payers, wholesalers, and public-health bodies are long-built strategic assets.

• Animal Health installed base: Brands, veterinary relationships, and digital livestock-identification and monitoring platforms give Merck durable positions beyond human pharmaceuticals.

These assets matter because they create both operating leverage and barriers to entry. Once Merck has a successful medicine and the capacity to supply it, returns can be very strong. The flip side is that the company must keep reinvesting to replenish its intangible asset base before patents expire.

20. What Is the Technology Strategy of Merck?

Merck’s technology strategy is not about selling enterprise software. It is about using technology to improve scientific productivity, speed development, strengthen manufacturing, and make selected offerings more differentiated.

• Technology as an internal enabler: Merck invests in digital research tools, data platforms, automation, advanced analytics, and manufacturing technologies that can improve cycle times and decision quality.

• Technology in the product offering: In Animal Health, technology is part of the customer value proposition through identification, traceability, and monitoring systems. In human health, technology matters in formulation, delivery, biomarker strategy, and complex biologics manufacturing.

• Technology and competitiveness: The more Merck relies on biologics, specialty care, and complex launches, the more process technology, digital systems, and high-quality data become central to execution.

In short, Merck’s technology strategy is mostly an enabler of scientific and operating advantage, with a more visible customer-facing technology component in Animal Health.

21. What Is the R&D Strategy of Merck?

R&D is central to Merck’s identity and economics. The company’s research strategy combines internal discovery with aggressive external sourcing of assets, technologies, and platforms.

• Focus on selected therapeutic areas: Merck has prioritized oncology, vaccines, infectious disease, specialty care, and, increasingly, adjacent areas such as immunology and cardiopulmonary medicine.

• Internal science plus external science: Merck does not rely only on its own labs. Transactions such as Acceleron, Prometheus, Harpoon, and the Daiichi Sankyo collaboration show a deliberate R&D model that buys external innovation where it can accelerate the pipeline.

• Franchise-building development: Merck often develops assets not as isolated products but as platform franchises, with multiple indications, combinations, and lifecycle paths. Keytruda is the clearest example.

• Biomarkers and precision medicine: In oncology especially, Merck’s R&D approach depends on data, patient segmentation, and trial designs that can expand or defend treatment relevance.

• Late-stage pipeline renewal: Recent dealmaking suggests Merck is especially focused on bringing in late-stage or platform assets that can contribute within a commercially relevant time frame.

Merck’s reported R&D expense can be affected by large acquired in-process research and development charges, so year-to-year reported figures can overstate or understate the steady-state operating commitment. Strategically, though, the message is clear: Merck is willing to spend heavily on R&D and business development to preserve long-term innovation leadership.

22. What Is the Finance Strategy of Merck?

Merck’s finance strategy is built around using cash flow from major franchises to fund three priorities: internal R&D, external business development, and shareholder returns, with manufacturing investment as a necessary fourth claim on capital.

• Reinvestment first: Merck allocates substantial capital to research, clinical development, and capacity expansion, especially where supply can constrain high-value products.

• Active balance-sheet use: The company has shown a willingness to use its balance sheet for meaningful acquisitions such as Acceleron and Prometheus.

• Dividend support: Like many large pharmaceutical companies, Merck supports a regular dividend, which signals confidence in cash-generation durability.

• Buybacks are secondary to strategic reinvestment: Merck can repurchase shares, but its recent pattern suggests that science-led M&A and internal investment are more strategically important than maximizing near-term capital return.

• Working capital and cash conversion: Inventory, launch spending, and manufacturing build-outs can affect near-term cash conversion, especially in vaccines and biologics.

Overall, Merck’s finance strategy supports the broader corporate goal of converting today’s blockbuster cash flows into tomorrow’s diversified pipeline and launch base.

23. What Major Acquisitions Has Merck Made?

Acquisitions are an important part of Merck’s strategy, though the company is not a constant serial acquirer. When it does deals, they are usually aimed at science, platforms, or portfolio reshaping rather than pure scale.

Merck’s recent deal pattern shows a clear logic: buy or license targeted assets that can help replace future Keytruda concentration, especially in oncology, immunology, and specialty care.

24. How Companies Like Merck Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Merck use Umbrex when they want that level of problem-solving capability without hiring a full traditional consulting team. For a science-driven company managing major launches, pipeline diversification, manufacturing investments, and AI adoption, independent consultants can be especially useful for focused, high-stakes projects that need senior talent and fast execution.

• Post-Keytruda portfolio strategy and scenario planning, including revenue-risk mitigation and diversification priorities.

• Launch excellence support for products such as Winrevair and new vaccine candidates, including field-force design, account prioritization, and launch war-room management.

• Oncology portfolio prioritization across internal programs, partnerships, and acquired assets such as antibody-drug conjugates and T-cell engagers.

• M&A integration management for biotech acquisitions, including operating-model design, synergy capture, and governance of retained science teams.

• Manufacturing-network and capacity-planning optimization for biologics and vaccines, including bottleneck analysis and capital-project PMO support.

• Procurement and supplier-risk diagnostics for sterile fill-finish components, single-use systems, and other constrained inputs.

• Market-access and pricing strategy projects addressing payer dynamics, international price corridors, and product-level contracting choices.

• Animal Health growth strategy work, including go-to-market design for digital livestock monitoring and cross-selling plans across veterinary channels.

• AI use-case prioritization in R&D, clinical operations, pharmacovigilance, and manufacturing, followed by pilot design and implementation support.

• SG&A productivity, shared-services redesign, and commercial-operations improvement across Merck’s global footprint.